Integrated Filing- Financial

Strides Pharma Science Limited has announced a board meeting focused on the integrated filing of financials for the quarter and nine months ended December 31, 2024. The unaudited consolidated financial results indicate total revenues from subsidiaries amounting to Rs 1,970 million for the quarter, with a reported consolidated net profit after tax of Rs 133 million.

The company's recent restructuring due to a NCLT-approved demerger, alongside the amalgamation of Strides Alathur, suggests a strategic realignment aimed at optimizing operations.

This development could lead to a positive outlook among investors, signaling improved financial management and operational efficiency moving forward.